Thabiti Athumani Mbaga

Mr. Thabiti Athumani Mbaga


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
SJSaid Abdallah Jongo
Said Abdallah Jongo
LCL. W. Preston Church
L. W. Preston Church
VNVicente Urbano Nsue Ndong Nchama
Vicente Urbano Nsue Ndong Nchama
AHAli Hamad
Ali Hamad
RCRaul Chuquiyauri
Raul Chuquiyauri
TRThomas L. Richie
Thomas L. Richie
: Plasmodium falciparum sporozoite (PfSPZ) Vaccine is composed of radiation-attenuated, aseptic, purified cryopreserved PfSPZ. Multiple clinical trials empirically assessing two to six doses have shown multi-dose priming (two to four doses the first week) to be optimal for protection in both 4- and 16-week regimens. In this randomized, double-blind, normal saline (NS) placebo-controlled trial, four groups (G) of 18- to 32-year-old Equatoguineans received multi-dose priming regimens with or without a delayed final dose at 4 or 16 weeks. The regimens were G1: days 1, 3, 5, 7, and 113; G2: days 1, 3, 5, and 7; G3: days 1, 3, 5, 7, and 29; and G4: days 1, 8, and 29. All doses were 9 × 105 PfSPZ. Tolerability, safety, immunogenicity, and vaccine efficacy (VE) against homologous controlled human malaria infection (CHMI) 6–7 weeks after vaccination were assessed to down-select the best regimen. All four regimens were safe and well tolerated, with no significant differences in adverse events (AEs) between vaccinees (N = 84) and NS controls (N = 20) or between regimens. Out of 19 controls, 13 developed Pf parasitemia by quantitative polymerase chain reaction (qPCR) after CHMI. Only the vaccine regimen administered on study days 1, 8, and 29 gave significant protection (7/21 vaccinees versus 13/19 controls infected, VE 51.3%, P = 0.03, Barnard’s test, two-tailed). There were no significant differences in antibodies against Pf circumsporozoite protein (PfCSP), a major SPZ antigen, between protected and nonprotected vaccinees or controls pre-CHMI. The six controls not developing Pf parasitemia had significantly higher antibodies to blood stage antigens Pf exported protein 1 (PfEXP1) and Pf merozoite surface protein 1 (PfMSP1) than the controls who developed parasitemia, suggesting naturally acquired immunity against Pf limited infections in controls. This study identified a safe, protective, 4-week, multi-dose prime vaccination regimen for assessment in future trials of PfSPZ Vaccine.

Verified
Journal Article
Open access
PDF file
Kamaka Ramadhani KassimuKamaka Ramadhani Kassimu
Kamaka Ramadhani Kassimu
FMFlorence Milando
Florence Milando
JOJustin Omolo
Justin Omolo
AMAbel Mdemu
Abel Mdemu
GNGloria Nyaulingo
Gloria Nyaulingo
SASalim Abdulla
Salim Abdulla
Background: Though Maytenus senegalensis is one of the medicinal plants widely used in traditional medicine to treat infectious and inflammatory diseases in Africa, there is a lack of safety data regarding its use. Therefore, the study aimed to asselss the safety and tolerability of the antimalarial herbal remedy M. senegalensis. Material and Methods: The study design was an open-label, single-arm, dose-escalation. Twelve eligible male healthy Tanzanians aged 18 to 45 years were enrolled in four study dose groups. Volunteers’ safety and tolerability post-investigational-product administration were monitored on days 0 to 7,14, and 56. Results: There were no deaths or serious adverse events in any of the study groups, nor any adverse events that resulted in premature discontinuation. The significant mean changes observed in WBC (p = 0.003), Neutrophils (p = 0.02), Lymphocytes (p = 0.001), Eosinophils (p = 0.009), Alanine aminotransferase (p = 0.002), Creatinine (p = 0.03) and Total bilirubin (p = 0.004) laboratory parameters were not associated with any signs of toxicity or clinical symptoms. Conclusions: M. senegalensis was demonstrated to be safe and tolerable when administered at a dose of 800 mg every eight hours a day for four days. This study design may be adapted to evaluate other herbal remedies.

30 September 2025 in Viruses
Verified
Journal Article
Open access
PDF file
RSRobert David Sumaye
Robert David Sumaye
ABAna Perola Drulla Brandao
Ana Perola Drulla Brandao
FCFrank Chilanga
Frank Chilanga
GPGoodluk Paul
Goodluk Paul
GMGrace Mwangoka
Grace Mwangoka
BBBrian H. Bird
Brian H. Bird
Rift Valley fever (RVF) is a re-emerging vector-borne zoonotic disease that causes outbreaks in humans and animals across Africa. To better understand RVF at human–animal interfaces, a prospective longitudinal survey of people, livestock, and mosquitoes was conducted from 2016 to 2018, in two regions of Tanzania, with distinct climatic zones (Iringa and Morogoro). Molecular and serological tools for testing (RT-qPCR and IgM/IgG ELISA) for RVF virus (RVFV) were used to assess infection and exposure in people and animals. Mosquitoes were collected quarterly from 10 sentinel locations. In total, 1385 acutely febrile humans, 4449 livestock, and 3463 mosquito pools were tested. In humans, IgM seroprevalence was 3.75% (n = 52/1385), and overall seroprevalence (IgM and/or IgG positive) was 8.30% (n = 115/1385). People from Iringa had a higher exposure risk than those from Morogoro (aOR 2.63), and livestock owners had an increased risk compared to non-owners (aOR 2.51). In livestock, IgM seroprevalence was 1.09%, while overall seroprevalence was 10.11%. A total of 68.4% of herds had at least one seropositive animal. Sentinel animal follow-up revealed that the probability of seroconversion was significantly higher in Morogoro. Low-level RVFV RNA was detected in 8 human and 22 mosquito pools. These findings indicate active transmission among vectors, livestock, and people during the study period, highlighting the need for One Health surveillance approaches for RVFV and other arboviruses.

4 June 2025 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
MMMaría Silvia Angué López Mikue
María Silvia Angué López Mikue
SJSaid Abdallah Jongo
Said Abdallah Jongo
VNVicente Urbano Nsue Ndong Nchama
Vicente Urbano Nsue Ndong Nchama
ASAli Hamad Said
Ali Hamad Said
AMAli Mtoro
Ali Mtoro
SASalim Abdulla
Salim Abdulla
: A malaria control program established in 2004 on Bioko Island, Equatorial Guinea, achieved significant reductions in malaria prevalence; however, progress subsequently stalled, leading to a proposal to develop and implement a highly effective malaria vaccine to increase impact. After conducting clinical trials of Sanaria® (Rockville, MD) Plasmodium falciparum (P. falciparum) sporozite vaccines against P. falciparum malaria, which demonstrated safety and efficacy, a larger phase 3 trial was planned to support vaccine licensure for specific target populations and eventual island-wide malaria elimination. The Equatorial Guinea Pilot Study for Recruitment, Screening and Participant Registry (EGRESPAR) assessed the health status of the target population and generated a registry of eligible children and adults. Households in areas with malaria prevalence ≥15% were randomly selected, aiming to register 2,100 healthy Equatoguineans divided equally into age groups of 1.5–9, 10–17, and 18–50 years. A total of 6,493 individuals from 1,807 households, who considered themselves or their children to be healthy, completed questionnaires; 2,021 were screened using phase 3 enrollment criteria, 643 were excluded, and 1,378 were entered into the registry. Among those screened, 13.6% had Plasmodium, 1.8% had Loa loa, 4.8% had hepatitis B, 0.5% had hepatitis C, and 2.1% had HIV. Adults were twice as likely to have clinically relevant medical conditions, such as obesity, hypertension, or diabetes, meeting exclusion criteria compared to children. In conclusion, there was a significant prevalence of infections and chronic medical conditions among Bioko Island residents who considered themselves or their children to be healthy and interested in clinical research participation, particularly in adults. The EGRESPAR successfully generated a registry to support the initiation of a large-scale phase 3 vaccine trial.